
View larger version (25K):
[in a new window]
|
Fig. 1. Treatment with dNJ prevents association of the core glycosylated Shaker protein with calnexin. (A) Structure of the 14-residue core glycan is shown. Glucose ( ), mannose ( ) and N- acetylglucosamine ( ). Arrows indicate sites of trimming by ER glucosidases I and II (ER Glu I and II) and ER mannosidases I and II (ERMI and II). Drugs that inhibit each step are shown in parentheses: dMJ, deoxymannojirimycin; dNJ, deoxynojirimycin; KIF, kifunensine; SWN, swainsonine. (B) Adjacent lanes showing the mobility of the immature, core-glycosylated form of the Shaker protein from cells incubated in the absence (-) or presence (+) of dNJ. When present, dNJ was added before the starvation step and was present throughout the pulse and chase periods. (C) Cells expressing the wild-type Shaker protein or an unglycosylated mutant (N259Q+N263Q) were metabolically labeled for 5 minutes, chased in nonradioactive medium for 0 or 10 minutes, as noted, and lysed with detergent. When present (+), dNJ was added before the starvation step and was present throughout the pulse and chase periods. Proteins were precipitated sequentially with antibodies directed against calnexin and Shaker (Nagaya et al., 1999 ). The open arrowhead denotes the position of the immature form of the Shaker protein. The open circle indicates the position of a nonspecific background band of variable intensity, which is also seen in untransfected cells upon immunoprecipitation with the Shaker antiserum (data not shown).
|